The products containing probiotic Lactobacillus plantarum HY7712 having activity preventing from the atherogenic legion formation and foam cell formation, which caused heart disease and stroke as effective component
The present invention relates to a product containing Lactobacillus plantarum HY7712 as an active ingredient which inhibits the formation of atherogenic lesions and foam cells which cause heart disease and stroke. The Lactobacillus plantarum HY7712 according to the present invention inhibits: oxidative damages in human macrophages； expression of CD36, SR-A, SR-B1 which are LDL receptors and scavanger receptors； formation of foam cells of the macrophages by increasing expression of ABCA1 and ABCG1； and formation of atherogenic lesion by inhibiting expression of macrophage adhesion molecules inside vessels, thus the Lactobacillus plantarum HY7712 can be variously used in pharmaceutical compositions, health supplements, functional drinks, fermented products, and the likes having inhibition effects of foam cell formation and atherogenic lesion formation.본 발명은 심장질환 및 뇌졸중을 유발하는 거품세포 형성 억제 및 혈관 병변형성 억제활성을 가지는 락토바실러스 플란타룸 HY7712를 유효성분으로 함유하는 제품에 관한 것으로서, 본 발명에 따른 락토바실러스 플란타룸 HY7712는 사람의 대식세포에서 산화적 데미지를 억제, LDL receptor 및 scavanger receptor인 CD36, SR-A, SR-B1 발현을 억제하며, ABCA1, ABCG1 발현을 증진시켜 대식세포의 거품세포 형성을 억제하고, 혈관 내 대식세포 부착물질 발현을 억제하여 혈관 병변형성을 억제하는 효과를 가지고 있어 심장질환 및 뇌졸중을 유발하는 거품세포 형성 억제 및 혈관 병변형성 억제효과를 가지는 약학적 조성물, 건강기능식품, 기능성음료, 발효제품 등 다양하게 이용될 수 있다.
